NCT06701812

Digoxin Medulloblastoma Study

Evaluation of Digoxin for Relapsed Non-WNT, Non-SHH Medulloblastoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (estimated)
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
• Sex: All
• Age: 12 Months – 30 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.

Conditions

• Medulloblastoma
• Medulloblastoma, Non-WNT/Non-SHH

Interventions

Type	Name	Description
DRUG	Digoxin	2.5-10 mcg/kg/day orally divided twice daily or once daily based on age on a continuous dosing schedule.

Timeline

• Start date: 2026-01-15
• Primary completion: 2027-02-01
• Completion: 2027-02-01
• First posted: 2024-11-22
• Last updated: 2026-02-27

Locations

15 sites across 1 country: United States

Regulatory

• FDA-regulated drug study